Literature DB >> 1016834

Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil.

R J Cross, R W Glashan, C S Humphrey, R G Robinson, P H Smith, R E Williams.   

Abstract

The cytotoxic drug combination of adriamycin and 5-fluorouracil has resulted in a 35% objective response in 20 patients with advanced bladder cancer. This has been achieved with minimal toxicity and on an out-patient basis. If the survival rate of patients with invasive bladder cancer is to be improved it seems likely that some form of systemic treatment will need to be added to the local measures currently in use. Further studies of different chemotherapeutic agents should help to define an effective and safe form of adjunvant therapy.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1016834     DOI： 10.1111/j.1464-410x.1976.tb06708.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN： 0007-1331


  12 in total

1.  Chemotherapy in bladder cancer.

Authors: 
Journal:  Br Med J       Date:  1977-12-17

Review 2.  Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.

Authors:  F M Torti; W G Harker
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.

Authors:  A Maru; H Akaza; S Isaka; K Koiso; T Kotake; T Machida; Y Matsumura; Y Nakagami; T Niijima; K Obata
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Intra-arterial adriamycin chemotherapy for bladder cancer. Semiselective intra-arterial chemotherapy with compression of the femoral arteries at the time of injection.

Authors:  T Uyama; S Moriwaki; M Yonezawa; J Fujita
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.

Authors:  T Kotake; M Usami; T Miki; M Kuroda; K Obata; M Osafune; H Fujioka; Y Takasugi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group.

Authors:  T Ueda; S Naito; A Iguchi; K Sagiyama; Y Osada; A Ariyoshi; T Omoto; J Kumazawa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 7.  Chemotherapy of advanced transitional-cell carcinoma of the bladder.

Authors:  R S Miller; F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Results of systemic chemotherapy of advanced bladder carcinomas (phase II study).

Authors:  G Stadie; A Möller; H Müller; D Katenkamp; H Urban; D Kob
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

9.  Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results.

Authors:  T Ueda; A Iguchi; K Sagiyama; Y Osada; A Ariyoshi; T Omoto; J Kumazawa
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  The chemotherapy of advanced bladder cancer.

Authors:  D W Newling; G Stoter; R Sylvester; M de Pauw
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.